Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Sliding Today

By Keith Speights – Aug 27, 2021 at 11:47AM

Key Points

  • European regulators are allowing a partner's facility in Spain that manufactures Moderna's COVID-19 vaccine to operate while an investigation into contamination issues moves forward.
  • Investors could be concerned about potential production delays if more problems are found.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be concerned about potential manufacturing issues at a contract manufacturing facility.

What happened

Shares of Moderna (MRNA 1.59%) were sliding 3.8% lower as of 11:26 a.m. EDT on Friday. The decline came even with a positive development for the company. The European Union is allowing the production of Moderna's COVID-19 vaccine to continue at a facility in Spain operated by the company's partner, Rovi. Contamination in some doses of the vaccine shipped to Japan was linked to a potential manufacturing issue at Rovi's plant.

However, EU regulators continue to investigate the contamination issue. Investors may be afraid that more problems could be found that could disrupt the production of Moderna's SpikeVax vaccine. 

Close-up of vaccine vials.

Image source: Getty Images.

So what

Any production delays could hurt Moderna's vaccine sales. However, there's no reason to expect any manufacturing hold-ups at this point.

The contamination problems weren't as bad as they could have been. Although Japan suspended the use of 1.63 million doses of Moderna's COVID-19 vaccine, no safety issues have been reported so far. 

Probably the main challenge for Moderna is that the vaccine stock is priced for perfection. Any concerns can give investors a reason to sell, creating downward pressure on the share price.

Now what

The European Medicines Agency will likely be able to determine the root cause of the contamination issues relatively quickly. That could put the problem to rest for Moderna -- or create even more headaches for the company.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Stock Quote
Moderna
MRNA
$175.91 (1.59%) $2.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.